



S Gillessen

Kontakt

S Gillessen

Publikationen (7)

STAMPEDE Investigators, Parikh O, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N, James N, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Brown J, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: *Ann Oncol* 2019; 30: 1992-2003. *Ann Oncol* 2020; 31:442.

James N, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Srihari N, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. *Ann Oncol* 2019

Hager S, Ackermann C, Jörger M, Gillessen S, Omlin A. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. *Ann Oncol* 2016; 27:975-84.

Omlin A, Forster T, Steinen M, Brügge D, Fretz C, Gillessen S, Hundsberger T. Maligne spinale Kompression - Prävention, Erkennung und "State of the Art"-Behandlung. *Schweiz Med Forum* 2014; 14:820-825.

Strebel R, Winterhalder R, Morant R, Pless M, U H, Fehr M, Gillessen S, Schmid H, Sulser T, Cathomas R. Multidisciplinary care in patients with prostate cancer: room for improvement. *Support Care Cancer* 2013; 21:2327-33.

Wittekind C, Nuver J, Nicolai N, Necchi A, Mayer F, Lotz J, Lorch A, Looijenga L, Laguna M, Krege S, Kollmannsberger C, Kliesch S, Huddart R, Oechsle K, Oldenburg J, Oosterhuis J, Winter C, Tandstad T, Souchon R, Sohaib A, Sedlmayer F, Schweyer S, Schrader M, Salvioni R, Rosti G, Rick O, Rajpert-De Meyts E, Powles T, Horwich A, Honecker F, Hentrich M, Daugaard G, Dahl A, Cohn-Cedermark G, Classen J, Clarke N, Cavallin-Stahl E, Cathomas R, Busch J, Bokemeyer C, Aparicio J, Altena R, Albers P, De Giorgi U, De Santis M, De Wit M, Heidenreich A, Hartmann J, Giwercman A, Gillessen S, Gietema J, Germá Lluch J, Fossa S, Fléchon A, Fizazi K, Fenner M, Dieckmann K, De Wit R, Beyer J. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. *Ann Oncol* 2012; 24:878-88.

von Moos R, Dummer R, Schönewolf N, Mamot C, Mjhić-Probst D, Schraml P, Moch H, Schläppi M, Cathomas R, Michielin O, Ochsenbein A, Gillessen S, Goldinger S, Simcock M, Seifert B, on behalf of the Swiss Group for Clinical Cancer Research (SAKK). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). *Ann Oncol* 2011; 23:531-6.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch